Cancer News and Research

Latest Cancer News and Research

Geron collaborates to explore hESC-based product for Alzheimer’s disease

Geron Corporation today announced that it has entered into a collaboration jointly funded by Geron and a University of California Discovery Research and Training Grant to investigate the therapeutic potential of its human embryonic stem cell (hESC)-based product, GRNOPC1, for Alzheimer’s disease. The company is currently developing GRNOPC1 for the potential treatment of spinal cord injury.

27 Jan 2010

Biomoda applauds Senator for introducing legislative bill for lung cancer screening

Cancer diagnostics company Biomoda, Inc. (www.biomoda.com) today applauded Nebraska State Sen. Bob Krist and his co-sponsors for introducing legislation to screen up to 500 Nebraska veterans for early-stage lung cancer.

27 Jan 2010

Jubilant Biosys, Endo Pharmaceuticals expand their drug discovery partnership in oncology

Jubilant Biosys Ltd., a subsidiary of Jubilant Organosys Ltd., and Endo Pharmaceuticals ( ENDP)., of Chadds Ford, Pa., U.S.A., announced today that they have expanded their drug discovery partnership in oncology, following the successful delivery of an early stage milestone.

27 Jan 2010

Helicos BioSciences adds new sequencing kits and run configurations for its Genetic Analysis System

Helicos BioSciences Corporation announced today the introduction of a series of new single molecule sequencing kits and run configurations for the Helicos® Genetic Analysis System that will expand its versatility for customers. These new products and configurations, available without any System hardware upgrades, offer customers the ability to tailor parameters of the System to the specific application and number of samples under study.

27 Jan 2010

Cinergy Health creates five steps to reduce childhood obesity

Cinergy Health, a nationwide health insurance agency providing guaranteed issue and short term major medical insurance programs, responds to the alarming rise in childhood obesity. One in three children in America is overweight or obese and one out of every five teenagers has a cholesterol level that increases the risk of heart disease.

27 Jan 2010

Study: PROSTVAC-VF vaccine effective in treating patients with metastatic prostate cancer

In a newly published clinical trial, patients with metastatic prostate cancer who received a vaccine of harmless poxviruses engineered to spur an immune system attack on prostate tumor cells lived substantially longer than patients who received a placebo vaccine, report researchers at Dana-Farber Cancer Institute and affiliated organizations.

27 Jan 2010

Burnham renamed to honor T. Denny Sanford's support

Burnham Institute for Medical Research (Burnham) announced today that philanthropist T. Denny Sanford has pledged $50 million to support and further expand and accelerate the Institute's leading-edge medical research. To honor Sanford, Burnham, has been renamed the Sanford-Burnham Medical Research Institute. This is the second gift Sanford has made to Burnham. In 2007, he directed $20 million through Sanford Health to create the Sanford Children's Health Research Center at Burnham.

27 Jan 2010

Asan Medical Center, Chemizon enter into multi-year research collaboration agreement

Asan Medical Center and Chemizon, the drug discovery division of Optomagic, Co. Ltd., announced today that they have entered into a multi-year research collaboration to discover and develop novel, small molecule oncology therapeutics.

27 Jan 2010

Health Canada approves first post-surgical treatment for patients with gastrointestinal stromal tumours

Patients with gastrointestinal stromal tumours (GIST) can now take action at an earlier stage of this rare form of cancer to reduce the risk of their disease returning following surgery. Novartis Pharmaceuticals Canada announced today that Gleevec* (imatinib mesylate) has received conditional approval by Health Canada for the adjuvant (post-surgical) treatment of adult patients who are at intermediate to high risk of disease recurrence following the surgical removal of GIST.

27 Jan 2010

Resveratrol supplements may offer potential benefits for cancer patients

For years, consumers and natural health advocates have been convinced of the benefits of resveratrol, the healthy by-product of red-wine grapes, but recently, the National Cancer Institute decided it was time to investigate further.

27 Jan 2010

Radient Pharmaceuticals' business plan submitted to NYSE Amex

US-based pharmaceutical company Radient Pharmaceuticals Corporation (RPC) announced today it has submitted a business plan to the New York Stock Exchange ("NYSE") Amex demonstrating its ability to achieve compliance with continued listing standards.

27 Jan 2010

MDRNA granted Chinese patent for use of nucleic acids in cancer treatment

MDRNA, Inc., a leading RNAi-based drug discovery and development company, today announced that the State Intellectual Property Office of the People's Republic of China (PRC) has issued a Notification of Granting Patent Rights for PRC 200480018784 which includes the use of nucleic acids, e.g., an siRNA, for the treatment of cancer. The patent describes modulation of claudins, which are proteins implicated in tumor progression and metastasis.

27 Jan 2010

Blue Foundation announces grants to improve Florida’s healthcare system

The Blue Foundation for a Healthy Florida, the philanthropic affiliate of Blue Cross and Blue Shield of Florida (BCBSF), is announcing grants to 11 Florida nonprofits that improve the health of in-need Floridians across the state. The grants are part of The Blue Foundation's biannual IMPACT Health Care (Improving Access to Health Care) grants program.

27 Jan 2010

NCCN updates the NCCN Clinical Practice Guidelines for Oncology for Ovarian Cancer

The National Comprehensive Cancer Network (NCCN) recently updated the NCCN Clinical Practice Guidelines for Oncology™ for Ovarian Cancer to reflect the addition of two preferred combination regimens for a specific cohort of patients based on data from recent clinical research studies.

27 Jan 2010

CT colonography remains an effective colorectal cancer screening tool for older individual

Computed tomographic colonography (CTC), also known as virtual colonoscopy, remains effective in screening older patients for colorectal cancer (CRC), produces low referral for colonoscopy rates similar to other screening exams now covered by Medicare, and does not result in unreasonable levels of additional testing resulting from extracolonic findings, according to a study published in the February issue of Radiology.

27 Jan 2010

Prometheus Laboratories executes commercialization agreement with Novartis

Prometheus Laboratories Inc., a specialty pharmaceutical and diagnostic company, today announced the execution of a commercialization agreement with Novartis under which Prometheus acquired exclusive rights to distribute, promote and sell PROLEUKIN® (aldesleukin) in the United States.

27 Jan 2010

EpiCept's NP-1 for treatment of PHN receives FDA orphan drug designation

EpiCept Corporation announced today that EpiCeptTM NP-1 has been granted orphan drug designation by the U.S. Food and Drug Administration (FDA) for the treatment of post-herpetic neuralgia (PHN). NP-1 is a prescription topical analgesic cream designed to provide long-term relief from the pain of peripheral neuropathies.

27 Jan 2010

Oxford Journals, IDSA sign new publishing partnership

Oxford Journals, a division of Oxford University Press, and the Infectious Diseases Society of America (IDSA), a leading professional society, have announced a new publishing partnership for IDSA's highly cited and internationally prestigious journals: Clinical Infectious Diseases (CID) and The Journal of Infectious Diseases (JID).

27 Jan 2010

Eating green leafy vegetables could reverse the effects of aflatoxin poisoning

Not only are the vitamins and minerals good for you, but eating greens could also save your life, according to a recent study led by the National Nuclear Security Administration's Lawrence Livermore National Laboratory scientists.

27 Jan 2010

Cornerstone Pharmaceuticals closes $6.17M Series B-4 private equity financing

Cornerstone Pharmaceuticals Inc., a privately held, clinical stage oncology-focused pharmaceutical company, has announced the closing of its Series B-4 private equity financing of $6,175,000. The Company plans to use the proceeds for its on-going phase I/II clinical trials of its lead cancer drug--CPI-613, research and development, and general corporate purposes.

27 Jan 2010

Cancer News and Research

Latest Cancer News and Research

Geron collaborates to explore hESC-based product for Alzheimer’s disease

Biomoda applauds Senator for introducing legislative bill for lung cancer screening

Jubilant Biosys, Endo Pharmaceuticals expand their drug discovery partnership in oncology

Helicos BioSciences adds new sequencing kits and run configurations for its Genetic Analysis System

Cinergy Health creates five steps to reduce childhood obesity

Study: PROSTVAC-VF vaccine effective in treating patients with metastatic prostate cancer

Burnham renamed to honor T. Denny Sanford's support

Asan Medical Center, Chemizon enter into multi-year research collaboration agreement

Health Canada approves first post-surgical treatment for patients with gastrointestinal stromal tumours

Resveratrol supplements may offer potential benefits for cancer patients

Radient Pharmaceuticals' business plan submitted to NYSE Amex

MDRNA granted Chinese patent for use of nucleic acids in cancer treatment

Blue Foundation announces grants to improve Florida’s healthcare system

NCCN updates the NCCN Clinical Practice Guidelines for Oncology for Ovarian Cancer

CT colonography remains an effective colorectal cancer screening tool for older individual

Prometheus Laboratories executes commercialization agreement with Novartis

EpiCept's NP-1 for treatment of PHN receives FDA orphan drug designation

Oxford Journals, IDSA sign new publishing partnership

Eating green leafy vegetables could reverse the effects of aflatoxin poisoning

Cornerstone Pharmaceuticals closes $6.17M Series B-4 private equity financing

Understanding the DNA Damage Response in Innate Immunity eBook

How microRNA is transforming science: From discovery to diagnostics

Advancing benzodiazepine detection

The Surgeon-Scientist Pioneering Regenerative Engineering

Cancer News and Research

Latest Cancer News and Research

Understanding the DNA Damage Response in Innate Immunity eBook

How microRNA is transforming science: From discovery to diagnostics

Advancing benzodiazepine detection

The Surgeon-Scientist Pioneering Regenerative Engineering

Newsletters you may be interested in